BriaCell Therapeutics Corp.
BCT.TO
TSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -16.94% | -14.79% | -41.28% | -566.40% | -457.09% |
| Total Depreciation and Amortization | 23.60% | 0.00% | 0.00% | -63.12% | 602.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 43.80% | 128.63% | -74.30% | 88.68% | 100.13% |
| Change in Net Operating Assets | 108.50% | -206.03% | 110.80% | -68.59% | -128.80% |
| Cash from Operations | 1.99% | -34.58% | -10.78% | -101.51% | -40.89% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -15,020.00% | 9,810.00% | 0.00% | -- | 53.33% |
| Cash from Investing | -15,140.95% | 9,810.00% | 0.00% | -1,517.99% | 53.33% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | 434.34% | -- | 206.80% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | 434.34% | -- | 206.80% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -409.18% | 3,592.11% | -257.80% | -2,571.74% | 240.27% |